Alpine Immune Sciences Inc (ALPN)
64.58
0.00 (0.00%)
USD |
NASDAQ |
May 01, 16:00
64.58
0.00 (0.00%)
After-Hours: 20:00
Alpine Immune Sciences Research and Development Expense (Quarterly): 22.93M for Dec. 31, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 22.93M |
| September 30, 2023 | 19.15M |
| June 30, 2023 | 19.24M |
| March 31, 2023 | 19.58M |
| December 31, 2022 | 18.76M |
| September 30, 2022 | 17.59M |
| June 30, 2022 | 17.59M |
| March 31, 2022 | 16.31M |
| December 31, 2021 | 15.36M |
| September 30, 2021 | 18.31M |
| June 30, 2021 | 14.63M |
| March 31, 2021 | 10.44M |
| December 31, 2020 | 9.055M |
| September 30, 2020 | 6.156M |
| June 30, 2020 | 7.096M |
| March 31, 2020 | 4.878M |
| December 31, 2019 | 5.799M |
| September 30, 2019 | 9.532M |
| June 30, 2019 | 10.17M |
| March 31, 2019 | 10.35M |
| Date | Value |
|---|---|
| December 31, 2018 | 8.931M |
| September 30, 2018 | 10.53M |
| June 30, 2018 | 5.718M |
| March 31, 2018 | 3.792M |
| December 31, 2017 | 3.71M |
| September 30, 2017 | 2.75M |
| June 30, 2017 | 0.359M |
| March 31, 2017 | 2.758M |
| December 31, 2016 | 5.656M |
| September 30, 2016 | 5.669M |
| June 30, 2016 | 6.424M |
| March 31, 2016 | 5.567M |
| December 31, 2015 | 4.293M |
| September 30, 2015 | 4.279M |
| June 30, 2015 | 4.465M |
| March 31, 2015 | 3.017M |
| December 31, 2014 | 2.822M |
| September 30, 2014 | 2.164M |
| June 30, 2014 | 3.363M |
| March 31, 2014 | 3.851M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
4.878M
Minimum
Mar 2020
22.93M
Maximum
Dec 2023
13.82M
Average
15.36M
Median
Dec 2021
Research and Development Expense (Quarterly) Benchmarks
| Vertex Pharmaceuticals Inc | 824.60M |
| Eliem Therapeutics Inc | 3.127M |
| Regeneron Pharmaceuticals Inc | 1.177B |
| Vera Therapeutics Inc | 20.78M |
| Eyenovia Inc | 4.065M |